Pandorum Technologies Private Limited, Bangalore, Karnataka 560100, India.
Brien Holden Eye Research Center, LV Prasad Eye Institute, Hyderabad, Telangana 500034, India.
Biomolecules. 2021 Apr 2;11(4):532. doi: 10.3390/biom11040532.
Biological materials derived from extracellular matrix (ECM) proteins have garnered interest as their composition is very similar to that of native tissue. Herein, we report the use of human cornea derived decellularized ECM (dECM) microparticles dispersed in human fibrin sealant as an accessible therapeutic alternative for corneal anterior stromal reconstruction. dECM microparticles had good particle size distribution (≤10 µm) and retained the majority of corneal ECM components found in native tissue. Fibrin-dECM hydrogels exhibited compressive modulus of 70.83 ± 9.17 kPa matching that of native tissue, maximum burst pressure of 34.3 ± 3.7 kPa, and demonstrated a short crosslinking time of ~17 min. The fibrin-dECM hydrogels were found to be biodegradable, cytocompatible, non-mutagenic, non-sensitive, non-irritant, and supported the growth and maintained the phenotype of encapsulated human corneal stem cells (hCSCs) in vitro. In a rabbit model of anterior lamellar keratectomy, fibrin-dECM bio-adhesives promoted corneal re-epithelialization within 14 days, induced stromal tissue repair, and displayed integration with corneal tissues in vivo. Overall, our results suggest that the incorporation of cornea tissue-derived ECM microparticles in fibrin hydrogels is non-toxic, safe, and shows tremendous promise as a minimally invasive therapeutic approach for the treatment of superficial corneal epithelial wounds and anterior stromal injuries.
生物材料来源于细胞外基质(ECM)蛋白,由于其组成与天然组织非常相似,因此引起了人们的兴趣。本文报告了使用人角膜脱细胞 ECM(dECM)微粒分散在人纤维蛋白密封剂中作为角膜前基质重建的可行治疗替代物的用途。dECM 微粒具有良好的粒径分布(≤10 µm),并保留了天然组织中存在的大多数角膜 ECM 成分。纤维蛋白-dECM 水凝胶的压缩模量为 70.83 ± 9.17 kPa,与天然组织匹配,最大破裂压力为 34.3 ± 3.7 kPa,并且表现出约 17 分钟的短交联时间。纤维蛋白-dECM 水凝胶可生物降解、细胞相容性、非致突变性、非敏感性、非刺激性,并支持封装的人角膜干细胞(hCSC)在体外的生长和维持其表型。在兔前板层角膜切除术模型中,纤维蛋白-dECM 生物粘合剂在 14 天内促进角膜再上皮化,诱导基质组织修复,并在体内与角膜组织整合。总体而言,我们的研究结果表明,将角膜组织衍生的 ECM 微粒掺入纤维蛋白水凝胶中是无毒,安全的,并且作为治疗浅层角膜上皮伤口和前基质损伤的微创治疗方法具有巨大的应用前景。